Amgen announces hold on Ph1 obesity candidate, pipeline cuts

Amgen said one of its early-stage obesity programs has been put on a clinical hold by the FDA, while reiterating its ambitions to become a major player in the crowded field. The company hasn’t revealed …
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks